TrialPloS one2017

DOT or SAT for Rifampicin-resistant tuberculosis? A non-randomized comparison in a high HIV-prevalence setting.

Erika Mohr et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.